Posted On: 06/21/2015 11:33:36 PM
Post# of 9144
Analytically your points make sense. The problem is that the NNLX technology runs up against very large established providers of competing tech in the US where the relationships are firmly established, kickbacks and free vacations to warm weather resorts in the winter are provided, and big users are inherently conservative and difficult to change behaviorally. This doesn't mean that sales can't be made to US consumers and I am certain they are, but they have to be made into niches where the company has the ability to supply in volume and where a competitor (particularly with petri dishes) won't simply sell its plates as a loss leader to undercut competition. Most medical supply producers sell a range of products and can take a hit on a lower cost one in order to block competition.
Sales in the US of the plates are undoubtedly ongoing, but the fact that there are no such competitors of scale in China or ones with a technology that can fit into the usage conditions found there provide NanoLogix with a significant competitive edge since its packaged petri system that far better withstands limited storage contexts and lasts far longer without high level cold storage, etc. is the product that makes a difference for the Chinese situation and capabilities. Africa, on one hand, is a basket case. The US in some ways has problems with adapting to the "best" technologies because the revenue rich institutions such as hospitals simply don't need to and can transfer costs to insurance rather than eat them. For some of the biggest potential users it is as if they are the medical equivalent of the DOD and defense contractors where cost efficiencies are threats to a bloated status quo rather than the blessing of an efficient and rational private sector. There are numerous consumers of the NNLX petri system to which to sell but they are niche consumers rather than the massive medical institutions.
I expect some dramatic shifts to occur with the N-Assay with its multiple well diagnostic capability that can be designed and customized for the specific range of needs of different users.
Sales in the US of the plates are undoubtedly ongoing, but the fact that there are no such competitors of scale in China or ones with a technology that can fit into the usage conditions found there provide NanoLogix with a significant competitive edge since its packaged petri system that far better withstands limited storage contexts and lasts far longer without high level cold storage, etc. is the product that makes a difference for the Chinese situation and capabilities. Africa, on one hand, is a basket case. The US in some ways has problems with adapting to the "best" technologies because the revenue rich institutions such as hospitals simply don't need to and can transfer costs to insurance rather than eat them. For some of the biggest potential users it is as if they are the medical equivalent of the DOD and defense contractors where cost efficiencies are threats to a bloated status quo rather than the blessing of an efficient and rational private sector. There are numerous consumers of the NNLX petri system to which to sell but they are niche consumers rather than the massive medical institutions.
I expect some dramatic shifts to occur with the N-Assay with its multiple well diagnostic capability that can be designed and customized for the specific range of needs of different users.
(0)
(0)
